Multiple sclerosis journal - experimental, translational and clinical · 2024
Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sauri-Suarez Sergio, Quiñones Sandra, De la Maza-Flores Manuel, Marin-Contreras Arturo, Playas-Pérez Gil, Bertado-Cortes Brenda, Frias-Marquez Francisco, Zuñiga-García Gilberto, Rodriguez-Leal Francisco, Blaisdell-Vidal Carlos, Gomez-Figueroa Enrique
Аннотация
BACKGROUND: Cladribine shows efficacy in multiple sclerosis (MS), but Latin American (LATAM) real-world data is limited, despite potential sociodemographic variations.
OBJECTIVE: Investigate baseline characteristics and clinical response in highly active MS patients in Mexico, identifying predictors of early treatment response.
METHOD: A multicenter cohort study analyzed retrospective data from individuals with "highly active" MS in the Cladribine Patient Support Program across 11 Mexican clinics. Criteria included one-year prior treatment with another disease-modifying treatment and recent relapse with specific MRI findings. Primary outcomes focused on achieving NEDA-3 status after 12 months.
RESULTS: In the follow-up, 67.5% maintained NEDA-3 status. Baseline EDSS scores decreased significantly from 1.50 to 1.00 (p = 0.011), with no confirmed disability worsening. No significant differences were observed between NEDA-3 achievers and non-achievers in demographic and clinical variables. No severe adverse events were reported.
CONCLUSION: Cladribine showed early and effective control of active MS in Mexican patients, demonstrating a secure profile with minimal adverse events. This study provides valuable real-world evidence in the LATAM context.
OBJECTIVE: Investigate baseline characteristics and clinical response in highly active MS patients in Mexico, identifying predictors of early treatment response.
METHOD: A multicenter cohort study analyzed retrospective data from individuals with "highly active" MS in the Cladribine Patient Support Program across 11 Mexican clinics. Criteria included one-year prior treatment with another disease-modifying treatment and recent relapse with specific MRI findings. Primary outcomes focused on achieving NEDA-3 status after 12 months.
RESULTS: In the follow-up, 67.5% maintained NEDA-3 status. Baseline EDSS scores decreased significantly from 1.50 to 1.00 (p = 0.011), with no confirmed disability worsening. No significant differences were observed between NEDA-3 achievers and non-achievers in demographic and clinical variables. No severe adverse events were reported.
CONCLUSION: Cladribine showed early and effective control of active MS in Mexican patients, demonstrating a secure profile with minimal adverse events. This study provides valuable real-world evidence in the LATAM context.